BASDAI, BASMI, and BASFI as a function of the fulfilment of the ASAS criteria and the decision to start anti-TNF treatment
| No fulfilment of ASAS criteria2 BASDAI <4 or no NSAID failing | Fulfilment of ASAS criteria2 BASDAI ⩾4 and failing NSAID | |||||
|---|---|---|---|---|---|---|
| Without anti-TNF at query (ccn = 131) | With anti-TNF at query (ccn = 34) | p Value | Without anti-TNF at query (ccn = 160) | With anti-TNF at query (ccn = 187) | p Value | |
| ASAS, ankylosing spondylitis study group; SEM, standard error of mean; ccn, number of complete cases; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; anti-TNF, anti-tumour necrosis factor alfa therapy | ||||||
| BASDAI | ||||||
| Mean | 3 | 3.7 | 0.041 | 6.2 | 6.5 | 0.028 |
| SEM | 0.13 | 0.34 | 0.11 | 0.09 | ||
| BASFI | ||||||
| Mean | 3.1 | 3.6 | 0.3 | 5.6 | 6.2 | 0.005 |
| SEM | 0.18 | 0.41 | 0.18 | 0.14 | ||
| BASMI | ||||||
| Mean | 3 | 3.3 | 0.5 | 3.3 | 4.3 | 0.002 |
| SEM | 0.25 | 0.38 | 0.22 | 0.26 | ||